Brief: Lipocine And Verity Pharma Enter Into License Agreement For Tlando Franchise In US And Canada

Lipocine

18/01/2024 13:10

Jan 18 (Reuters) - Lipocine Inc  LPCN.O :
    * LIPOCINE AND VERITY PHARMA ENTER INTO LICENSE AGREEMENT
FOR
TLANDO® FRANCHISE IN THE U.S. AND CANADA
    * LIPOCINE INC: UP TO $259 MILLION IN DEVELOPMENT AND
COMMERCIAL
SALES MILESTONES
    * LIPOCINE INC - UP TO $259 MILLION IN DEVELOPMENT AND
COMMERCIAL
SALES MILESTONES
    * LIPOCINE INC: LIPOCINE TO RECEIVE $11 MILLION LICENSE FEE
    * LIPOCINE INC: COMMERCIALIZATION OF TLANDO TRANSITIONS TO
VERITY
PHARMA EFFECTIVE FEB.1 2024
    * LIPOCINE INC - LIPOCINE RETAINS ALL RIGHTS FOR TERRITORIES
OUTSIDE UNITED STATES AND CANADA, AND ALL NON-TRT RIGHTS
GLOBALLY
    * LIPOCINE INC: VERITY PHARMA WILL BE RESPONSIBLE FOR
REGULATORY
AND MARKETING OBLIGATIONS IN U.S. AND CANADA, AND ALL FURTHER
DEVELOPMENT

Source text for Eikon:  ID:nPn9TPXDja 
Further company coverage:  LPCN.O 

 ((Reuters.Briefs@thomsonreuters.com;))